Masaru Matsuda sold $50k of ARQT
See Remarks at Arcutis Biotherapeutics, Inc.. 1,657 shares at an average of $30.23, traded Dec 1, 2025, filed Dec 3, 2025.
Score components
- +15RoleOfficer
- +7Trade size$50k at market
- 0Share of holdings soldSold 1.1% of holdings
- +15Cluster6 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001798679-25-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 1, 2025 | SOpen-market sale Common Stock10b5-1 | -1,657 | $30.23 | $50k | 150,641 | Dec 3, 2025 |
Related signals
Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $92k 3,674 shares | -3% | |
| 3Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $114k 4,730 shares | -12% | |
| 16Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $250k 9,989 shares | -8% | |
| 15Weak | Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $333k 11,500 shares | -10% | |
| 29Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $302k 10,000 shares | -11% | |
| 47Moderate | Arcutis Biotherapeutics, Inc. | Sue-Jean Lin director | $778k 25,272 shares | -49% | |
| 35Weak | Arcutis Biotherapeutics, Inc. | Todd Watanabe See Remarks | $1.5M 50,000 shares | -6% | |
| 42Moderate | Arcutis Biotherapeutics, Inc. | Halley E Gilbert director | $455k 16,532 shares | -43% | |
| 18Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $72k 2,550 shares | -2% | |
| 39Weak | Arcutis Biotherapeutics, Inc. | Neha Krishnamohan director | $939k 40,504 shares | -65% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.